123 related articles for article (PubMed ID: 11595281)
1. PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases.
Calvo P; Gouritin B; Brigger I; Lasmezas C; Deslys J; Williams A; Andreux JP; Dormont D; Couvreur P
J Neurosci Methods; 2001 Oct; 111(2):151-5. PubMed ID: 11595281
[TBL] [Abstract][Full Text] [Related]
2. Body distribution and in situ evading of phagocytic uptake by macrophages of long-circulating poly (ethylene glycol) cyanoacrylate-co-n-hexadecyl cyanoacrylate nanoparticles.
Huang M; Wu W; Qian J; Wan DJ; Wei XL; Zhu JH
Acta Pharmacol Sin; 2005 Dec; 26(12):1512-8. PubMed ID: 16297352
[TBL] [Abstract][Full Text] [Related]
3. Stealth PEGylated polycyanoacrylate nanoparticles for intravenous administration and splenic targeting.
Peracchia MT; Fattal E; Desmaële D; Besnard M; Noël JP; Gomis JM; Appel M; d'Angelo J; Couvreur P
J Control Release; 1999 Jun; 60(1):121-8. PubMed ID: 10370176
[TBL] [Abstract][Full Text] [Related]
4. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.
Calvo P; Gouritin B; Chacun H; Desmaële D; D'Angelo J; Noel JP; Georgin D; Fattal E; Andreux JP; Couvreur P
Pharm Res; 2001 Aug; 18(8):1157-66. PubMed ID: 11587488
[TBL] [Abstract][Full Text] [Related]
5. PEGylated polycyanoacrylate nanoparticles as salvicine carriers: synthesis, preparation, and in vitro characterization.
Li YP; Zhou ZH; Pei YY; Zhang XY; Gu ZH; Yuan WF
Acta Pharmacol Sin; 2001 Jul; 22(7):645-50. PubMed ID: 11749831
[TBL] [Abstract][Full Text] [Related]
6. Pegylated nanoparticles from a novel methoxypolyethylene glycol cyanoacrylate-hexadecyl cyanoacrylate amphiphilic copolymer.
Peracchia MT; Vauthier C; Desmaële D; Gulik A; Dedieu JC; Demoy M; d'Angelo J; Couvreur P
Pharm Res; 1998 Apr; 15(4):550-6. PubMed ID: 9587950
[TBL] [Abstract][Full Text] [Related]
7. Stealth PEG-PHDCA niosomes: effects of chain length of PEG and particle size on niosomes surface properties, in vitro drug release, phagocytic uptake, in vivo pharmacokinetics and antitumor activity.
Shi B; Fang C; Pei Y
J Pharm Sci; 2006 Sep; 95(9):1873-87. PubMed ID: 16795003
[TBL] [Abstract][Full Text] [Related]
8. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat.
Calvo P; Gouritin B; Villarroya H; Eclancher F; Giannavola C; Klein C; Andreux JP; Couvreur P
Eur J Neurosci; 2002 Apr; 15(8):1317-26. PubMed ID: 11994126
[TBL] [Abstract][Full Text] [Related]
9. PEGylated polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers.
Li YP; Pei YY; Zhou ZH; Zhang XY; Gu ZH; Ding J; Zhou JJ; Gao XJ
J Control Release; 2001 Apr; 71(3):287-96. PubMed ID: 11295221
[TBL] [Abstract][Full Text] [Related]
10. Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis.
Kim HR; Andrieux K; Gil S; Taverna M; Chacun H; Desmaële D; Taran F; Georgin D; Couvreur P
Biomacromolecules; 2007 Mar; 8(3):793-9. PubMed ID: 17309294
[TBL] [Abstract][Full Text] [Related]
11. [Influence of particle size and MePEG molecular weight on in vitro macrophage uptake and in vivo long circulating of stealth nanoparticles in rats].
Fang C; Shi B; Hong MH; Pei YY; Chen HZ
Yao Xue Xue Bao; 2006 Apr; 41(4):305-12. PubMed ID: 16856473
[TBL] [Abstract][Full Text] [Related]
12. Long circulating biodegradable poly(phosphazene) nanoparticles surface modified with poly(phosphazene)-poly(ethylene oxide) copolymer.
Vandorpe J; Schacht E; Dunn S; Hawley A; Stolnik S; Davis SS; Garnett MC; Davies MC; Illum L
Biomaterials; 1997 Sep; 18(17):1147-52. PubMed ID: 9259511
[TBL] [Abstract][Full Text] [Related]
13. Poly(ethylene glycol)-coated hexadecylcyanoacrylate nanospheres display a combined effect for brain tumor targeting.
Brigger I; Morizet J; Aubert G; Chacun H; Terrier-Lacombe MJ; Couvreur P; Vassal G
J Pharmacol Exp Ther; 2002 Dec; 303(3):928-36. PubMed ID: 12438511
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticles bearing polyethyleneglycol-coupled transferrin as gene carriers: preparation and in vitro evaluation.
Li Y; Ogris M; Wagner E; Pelisek J; Rüffer M
Int J Pharm; 2003 Jun; 259(1-2):93-101. PubMed ID: 12787639
[TBL] [Abstract][Full Text] [Related]
15. Stealth polycyanoacrylate nanoparticles as tumor necrosis factor-alpha carriers: pharmacokinetics and anti-tumor effects.
Li YP; Pei YY; Zhou ZH; Zhang XY; Gu ZH; Ding J; Zhou JJ; Gao XJ; Zhu JH
Biol Pharm Bull; 2001 Jun; 24(6):662-5. PubMed ID: 11411555
[TBL] [Abstract][Full Text] [Related]
16. In vivo fate of unimers and micelles of a poly(ethylene glycol)-block-poly(caprolactone) copolymer in mice following intravenous administration.
Liu J; Zeng F; Allen C
Eur J Pharm Biopharm; 2007 Mar; 65(3):309-19. PubMed ID: 17257817
[TBL] [Abstract][Full Text] [Related]
17. Effect of polymer architecture on surface properties, plasma protein adsorption, and cellular interactions of pegylated nanoparticles.
Sant S; Poulin S; Hildgen P
J Biomed Mater Res A; 2008 Dec; 87(4):885-95. PubMed ID: 18228249
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
19. A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles.
Garcia-Garcia E; Gil S; Andrieux K; Desmaële D; Nicolas V; Taran F; Georgin D; Andreux JP; Roux F; Couvreur P
Cell Mol Life Sci; 2005 Jun; 62(12):1400-8. PubMed ID: 15905957
[TBL] [Abstract][Full Text] [Related]
20. The effect of poly(ethylene glycol) coating and monomer type on poly(alkyl cyanoacrylate) nanoparticle interactions with lipid monolayers and cells.
Baghirov H; Melikishvili S; Mørch Y; Sulheim E; Åslund AKO; Hianik T; de Lange Davies C
Colloids Surf B Biointerfaces; 2017 Feb; 150():373-383. PubMed ID: 27842930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
